Worldwide \”Dermal Fillers Market\” is Estimated to grow at the CAGR of ~12.5% and is Projected to reach USD 10,008.4 million by 2023

“Dermal Fillers market”
Market Research Future published a Cooked research report on “Global Dermal Fillers Market Research Report – Forecast to 2023”– Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2023.

The global dermal fillers market is expected grow at a fast pace owing to an increasing trend of using anti-ageing treatments, and demand for various devices for dermatology procedures in the market. Rising awareness about skin care and extensive demand for diagnostic and treatment services for skin diseases also influence the growth of the market.

number of cosmetic surgeries as well as lifestyle changes further accelerate the market growth. There is an increases in the number of facial injectable surgeries performed on women, as their demand is increasing from last few years, thus boosting the development of the market. Around 91% of facial injectable surgeries are performed on women across the globe. Additionally, availability of well qualified and highly skilled healthcare professional such as dermatologist and surgeons increase the demand for dermal fillers and other dermatology devices and appliances in the market.

Technological advancement further determines the development of dermal fillers market as the key players are now engaged in product differentiation strategy, which is important to sustain the company`s growth and strength its geographical presence.

Get a sample report at .

Key Players in The Dermal Fillers Market:

ALLERGAN (Republic of Ireland), Dr. Korman Laboratories (Israel), GALDERMA (Switzerland), Integra Lifesciences (US), Merz Pharma (Germany), Sinclair Pharma (UK), and Teoxane laboratories (Switzerland). The major players focus on the development of products useful for particular segment such as nutritional products for adults, children and geriatric population. The major players focus on the development of products useful for particular segment such as nutritional products for adults, children and geriatric population.

Key Developments:

Strategic approaches adopted help the major players in the market to sustain their growth and develop their business in various geographical areas across the globe. Agreements and collaborations, mergers and acquisitions, and new product launches are various strategies followed by the key players. This help the companies to reach untapped markets in developing nations of the worlds, thus reducing the supply demand gap.


Allergan has a wind range of products which provides efficient treatment for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women’s health, urology and anti-infective therapeutic categories

June 2017: Allergan announces launch of artificial tear refresh optive mega-3.

June, 2017: Allergan announced the acquisition of Keller Medical, adding Keller Funnel to co’s leading plastic surgery portfolio.

March 2017: Allergan and Editas Medicine enter into strategic research and development alliance. This alliance is to discover and develop Crispr Genome editing medicines for eye diseases.


Galderma is a global leader in dermatology and has strategic partnerships with brands like Soolantra, Tri-Luma, Loceryl, BenzacEpiduo, Oracea, Differin, Mirvaso, Cetaphil, Excipial, Daylong, Restylane, Emervel and many other brands. The company focus on the production of innovative solutions in the field of dermatology for the treatment of various skin diseases such as acne, rosacea, psoriasis, steroid-responsive dermatoses, onychomycosis, pigmentary disorders, skin cancer and other various fields in skin care.

January 2017: Galderma launched two new dermal fillers. In December, Galderma received FDA approval for a pair of next-generation hyaluronic acid (HA) dermal fillers: Restylane Refyne and Restylane Defyne.

January 2017: Galderma announces approval of Azzalure in Europe for treatment of lateral canthal lines in adults. Azzalure, a product in-licensed from Ipsen, received positive opinion from the French regulatory authority, ANSM, for treatment of lateral canthal lines (crow’s feet), either alone or in combination with treatment of glabellar lines.

July 2016: Chugai and Galderma Announce Global License Agreement for Nemolizumab (CIM331), Novel Biologic for Skin Diseases. The primary aim of this agreement is to improve atopic dermatitis by breaking the itch-scratch cycle which has great expectation for nemolizumab.

January 2016: Maruho and Galderma to Join Forces in a Strategic Alliance in Japan. One of the major reasons of this strategic alliance is that galderma will permit maruho to additionally promote their products in japan in the field of dermatology.

Browse Complete Report at .

Integra Lifesciences:

February 2017: Integra Lifesciences plans to acquire Codman neurosurgery business from Johnson & Johnson.

February 2016: Integra Lifesciences Holdings Corp announces Service Alliance Agreement with PREZIO Health. By this Integra life science will have an authorized service provider for surgical devices and instruments.

May 2015: Integra Lifesciences completes acquisition of TEI Biosciences and TEI Medical. This acquisition Integra will expand their biomedical product profile with collagen based products strengthening the product portfolio of Integra Life Science.

The global dermal fillers market has been evaluated as a rapidly growing market and it is expected to continue growing in the near future. Increasing trend of using anti-ageing treatments, and demand to look younger are major drivers for the market growth. Women are getting more conscious about their looks that factor leading to increase in number of facial surgeries. Increasing treatments and surgeries are important driving forces of the market. Around 91% of facial injectable surgeries are performed on women. The number of surgeries performed in male population is also growing rapidly. Increasing awareness of various facial surgeries, new techniques, and visible effects are driving the growth for the market.

Major players of this market are funding for research and new product development to derive effective solution to the market. Innovative and advanced product development are also key factors for global dermal fillers market. Due to its rapid growth rate, many new companies are getting attracted towards this market. Hospitals are also working on introduction and implementation of new surgeries are leading the growth for the market. Increasing acceptance of tissue fillers and growing number of dermal filler surgeries in emerging economies of Asia and Latin America are another important driving forces of the market.

More Inquire at .

The Americas are holding the largest market share. The Americas mainly include North America and Latin America. North America is very important and highest revenue generator market for Dermal Fillers. Asia Pacific is the fastest growing market. Some major factors like increasing awareness of treatments, developing healthcare sector, availability of skilled medical professional, and rising per capita income as well as healthcare expenditure are driving the growth for Asia Pacific dermal fillers market. Europe dermal fillers is also growing significantly. Germany, UK, and France are the major markets while Eastern European dermal fillers market is also growing. France is holding largest market share in this market. Middle East & Africa dermal fillers market is expected to have limited growth mainly due to lack of awareness of treatments, limited access to the healthcare facilities and products, and slow adoption of new products etc. Due to developed healthcare infrastructure and high expenditure on healthcare, Middle East is dominating region as compared to Africa.

Media Contact
Company Name: Market Research Future
Contact Person: Akash Anand
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar, Pune –
City: Pune
State: Maharashtra
Country: India